Evidence map›Paper›PMID 34540694›Full record

ArticleFrontiers in oncology2021

Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage.

Gabriele Merati, Marianna Rossi, Anna Gallì, Elisa Roncoroni, Silvia Zibellini, Ettore Rizzo, Daniela Pietra, Cristina Picone, Barbara Rocca, Claudia Patricia Tobar Cabrera and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Gabriele MeratiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Marianna RossiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Anna GallìDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Elisa RoncoroniDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Silvia ZibelliniDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Ettore RizzoenGenome, Pavia, Italy.
Daniela PietraDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Cristina PiconeDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Barbara RoccaDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Claudia Patricia Tobar CabreraDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Eleonora GelliDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Eugenio SantacroceDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Luca ArcainiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Patrizia ZappasodiDivision of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Policlinico San Matteo Fondazione · ITUniversity of Pavia · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available. We investigated the genetic basis of 10 cases of ALAL diagnosed at our centre from 2008 and 2020, through a targeted myeloid and lymphoid sequencing approach. We show that this rare group of acute leukemias is enriched in myeloid-gene mutations. In particular we found that RUNX1 mutations, which have been found double mutated in 40% of patients and tend to involve both alleles, are associated with an undifferentiated phenotype and with lineage ambiguity. Furthermore, because this feature is typical of acute myeloid leukemia with minimal differentiation, we believe that our data strengthen the idea that acute leukemia with ambiguous lineage, especially those with an undifferentiated phenotype, might be genetically more closer to acute myeloid leukemia rather than acute lymphoblastic leukemia. These data enrich the knowledge on the genetic basis of ALAL and could have clinical implications as an acute myeloid leukemia (AML) - oriented chemotherapeutic approach might be more appropriate.

Indexed as

acute leukemia of ambiguous lineageacute undifferentiated leukaemiadouble mutationsmyeloid genesRunx1

Identifiers

PMID34540694
PMCPMC8444989
OpenAlexW3196689994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.